iVeena Delivery Systems

Executive Summary

iVeena Delivery Systems is a clinical-stage ophthalmology company developing novel eye drops for refractive diseases such as keratoconus and pediatric myopia. Its lead asset, IVMED-80, is licensed to Glaukos Corporation and targets keratoconus, a progressive corneal thinning disorder. The company's proprietary platform aims to cross-link and strengthen corneal tissue non-invasively. With a focus on disease modification rather than symptom management, iVeena holds potential in a large underserved market. However, the company remains private with limited disclosed financials, and its dependence on the Glaukos partnership for IVMED-80 development creates both validation and concentration risk. The recent absence of public pipeline updates suggests a quiet period ahead of key milestones. Overall, iVeena offers a compelling but early-stage opportunity in ophthalmic therapeutics, warranting cautious attention pending clinical data readouts.

Upcoming Catalysts (preview)

• Q1 2027Phase 2b/3 top-line data for IVMED-80 in keratoconus45% success
• Q4 2026Preclinical or Phase 1 initiation for pediatric myopia program30% success
• H2 2026Potential licensing or partnership expansion beyond Glaukos25% success